In this study, we analyzed the clinical and molecular characteristics of 87 lung cancer patients with mutated KRAS who had received monotherapy ICIs to identify the associations with the clinical outcomes of responses and overall survival (OS). This evidence concerns the gene KRAS and lung cancer.